When does dapagliflozin patent protection end (and what limits generic entry)?
Dapagliflozin’s market exclusivity is tied to a mix of primary patents and later “secondary” patents (covering specific formulations, combinations, dosing regimens, and related intellectual-property claims). As a result, generic and follow-on products may be delayed even after an initial patent term ends.
The most reliable way to estimate the earliest possible generic start date is to check the specific patent families and their projected expiration/term in the relevant country (U.S., EU/UK, etc.). Patent coverage can also differ across jurisdictions and can be extended by mechanisms such as patent term adjustments or extensions (where available).
For a patent-focused view of dapagliflozin’s exclusivity landscape, DrugPatentWatch.com tracks patent filings and status updates across markets: https://www.drugpatentwatch.com/ (search for “dapagliflozin” on the site).
Is there a single “loss of patent” date for dapagliflozin?
Usually not. People often look for one “loss of patent” date, but dapagliflozin can face multiple patent expirations in different years, with different claims expiring at different times. If any enforceable patent or supplementary protection still covers the marketed product (or an authorized generic/biosimilar “work-around”), generic entry can be blocked or delayed.
That’s why patent-watch databases are useful: they list each relevant patent and its expected expiration, rather than collapsing everything into one date.
How do patents affect generic (or follow-on) launch timing in practice?
Even when a patent’s nominal term ends, generic entry depends on:
- Whether any other patents covering the same product are still active
- Whether patent litigation has been filed or resolved (which can trigger stay periods in some regions)
- Whether regulatory submissions are allowed to proceed for the specific indication and product version
So “loss of patent” can mean different things:
- The first year when at least one major patent expires
- The first year when the last blocking patent expires
- The actual market launch date after regulatory approval and any litigation-driven delays
What about U.S. vs EU/UK—do expiration dates differ?
Yes. Patent expiration (and any extensions) can differ by country because filing dates, claim sets, and extension rules are not identical worldwide. A patent family that provides strong coverage in the U.S. may expire later (or earlier) than its counterpart in the EU or UK.
To answer “loss of patent” accurately for the region you care about, you need the country-specific patent list and expirations. DrugPatentWatch.com is a commonly used starting point for that comparison: https://www.drugpatentwatch.com/ (search “dapagliflozin”).
What should you check to confirm the actual exclusivity end date?
If you’re trying to pin down when dapagliflozin becomes fully “free” for generic competition, the key items to verify are:
- The latest-expiring patents in each relevant patent family
- Whether there are patents for specific combinations or dose forms (important because dapagliflozin is used in multiple products/combos)
- Whether there are ongoing litigation events that affect launch timing
DrugPatentWatch.com can help identify which patents are still active and when they are expected to expire, but you still need to map those patents to the specific marketed product(s) and indication(s) you care about.
Source
- DrugPatentWatch.com (dapagliflozin patent tracking): https://www.drugpatentwatch.com/
If you tell me the country (U.S., EU, UK, or another) and whether you mean dapagliflozin alone (e.g., Farxiga) or a specific combination product, I can narrow the answer to the likely last blocking patent expirations for that exact target.